Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Dr Reddy's Labs Q2 Results: Profit falls 15% YoY to Rs 1,255 crore, revenue up 17%
Healthcare major Dr Reddy's Labs on Tuesday reported 15% drop in its consolidated net profit at Rs 1,255 crore in the second quarter. It was Rs 1,480 crore in the year-ago quarter.Revenue from operations in the same period stood at Rs 8,
Titan, GAIL, Oil India, Dr Reddy's Labs Q2 Results Today — Earnings Estimates
Key Q2 earnings announcements today from Titan, GAIL, Oil India, Dr Reddy's Labs, and Mankind Pharma are anticipated to reveal strong financial performance across diverse sectors in India.
Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%
Dr Reddy's Lab’s average revenue will potentially increase 12 per cent Y-o-Y to Rs 7,734 crore as against Rs 6,902 crore in Q2FY24. On a quarterly basis, the revenues may rise by 0.4 per cent. The pharma company registered revenues of Rs 7,696 crore in the June quarter of FY25.
Dr Reddy's Labs Q2 Preview: Healthy double-digit revenue growth seen, but PAT may fall
For the July-September 2024 period, net profit is expected to decline by 3% year-on-year, based on the average estimate from four brokerages. Sales, however, are projected to increase by 13% year-on-year,
Dr. Reddy's Laboratories Ltd reports Rs. 1255.3 crores consolidated PAT in Q2 FY2025
The Board of Directors of Dr. Reddys Laboratories Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 FY2024-25.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
Lack of strong launch pipeline keep brokerages neutral over Dr Reddy's Labs
Dr Reddy's revenue surged by 17 percent to an all-time high of ... Despite this, it reported a 15 percent on year drop in ...
Dr Reddy's clocks highest-ever revenue in Q2; net profit down 9.5%
Hyderabad-based Dr Reddy's Laboratories (DRL) posted a 9.5 per cent year-on-year (Y-o-Y) decline in its consolidated ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
cnbctv184h
Healthcare major Dr Reddy's Q2 net profit falls, revenue gains momentum
Healthcare major Dr Reddy's Laboratories reported a 15% decline in its consolidated net profit, totalling ₹1,255 crore ...
Dr Reddy's R&D expenses to stay around 8.5% in FY25, to launch key biosimilar in 2027
Much like the trend in the domestic pharma industry, Dr Reddy's Laboratories is investing heavily in research and development aimed at ramping up the biosimilars, generics, and biologics segments.